Intranasal Booster Shots To Go On Trial Approved By DCGI
We could be looking at intranasal booster dose against Covid-19 soon, as Bharat Biotech has now been allowed by The Drugs Controller General of India (DCGI) to conduct trials for the same.
Trials will be conducted in nine different locations in the country. This would be the Phase-3 clinical trial. The intranasal dosage will have the great advantage of mass usage. The nasal vaccine, BBV154 is slated to be a huge success as it promises to stimulates immune responses at the site of infection — the nose — and is very effective in blocking infection and transmission of Covid-19.
It is worth noting that a nasal spray or booster of this kind can be self-dosed and will therefore not need experienced or trained staff to administer the same. With approval of the Phase-3, the trials will evaluate BBV154 nasal vaccine for both the second dose primary schedule and booster dose schedule.
The booster shot will not immediately be available in retail. People will still have to contact hospitals to get their booster shots. It is worth noting that the fresh approval comes soon after Bharat Biotech’s Covaxin and Serum Institute of India’s Covishield were cleared for sale in the market.
Owing to the mutation speed of the Covid-19 vaccine, it is becoming imperative that people continue to protect themselves from being infected by the virus. While the first two vaccines create a shield of protection, they are still to give 100 percent protection from contracting the virus. There is a debate going on about how quickly should one get oneself vaccinated, owing to the fact that one can still contract the virus. Medical practitioners are of the mind that it is still safer to get yourself vaccinated to prevent severe exposure to the virus.